Literature DB >> 19490586

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.

Lynn R Goldin1, Magnus Björkholm, Sigurdur Y Kristinsson, Jan Samuelsson, Ola Landgren.   

Abstract

Myeloproliferative neoplasms (MPNs) are a group of closely related stem-cell-derived clonal proliferative diseases. Most cases are sporadic but first-degree relatives of MPN patients have a five- to seven-fold increased risk for developing an MPN. The tumors of most patients carry a mutation in the Janus kinase 2 gene (JAK2(V617F)). Recently, three groups have described a strong association of JAK2 germline polymorphisms with MPN in patients positive for JAK2(V617F). The somatic mutation occurs primarily on one particular germline JAK2 haplotype, which may account for as much as 50% of the risk to first-degree relatives. This finding provides new directions for unraveling the pathogenesis of MPN.

Entities:  

Year:  2009        PMID: 19490586      PMCID: PMC2689447          DOI: 10.1186/gm55

Source DB:  PubMed          Journal:  Genome Med        ISSN: 1756-994X            Impact factor:   11.117


  17 in total

1.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

2.  Disease anticipation in familial myeloproliferative neoplasms.

Authors:  Elisa Rumi; Francesco Passamonti; Cristina Picone; Matteo Giovanni Della Porta; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

Review 3.  Essential thrombocythemia: a review of diagnostic and pathologic features.

Authors:  Steven Sanchez; April Ewton
Journal:  Arch Pathol Lab Med       Date:  2006-08       Impact factor: 5.534

Review 4.  Oncogenes in myeloproliferative disorders.

Authors:  Ayalew Tefferi; D Gary Gilliland
Journal:  Cell Cycle       Date:  2007-03-24       Impact factor: 4.534

5.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

6.  Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.

Authors:  Christine Bellanné-Chantelot; Isabelle Chaumarel; Myriam Labopin; Florence Bellanger; Véronique Barbu; Claudia De Toma; François Delhommeau; Nicole Casadevall; William Vainchenker; Gilles Thomas; Albert Najman
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

7.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

8.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

Review 9.  Biology and treatment of primary myelofibrosis.

Authors:  Ronald Hoffman; Damiano Rondelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

10.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

Authors:  Francesco Passamonti; Elisa Rumi; Ester Pungolino; Lucia Malabarba; Paola Bertazzoni; Marina Valentini; Ester Orlandi; Luca Arcaini; Ercole Brusamolino; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
Journal:  Am J Med       Date:  2004-11-15       Impact factor: 4.965

View more
  3 in total

1.  Distinct germ line polymorphisms underlie glioma morphologic heterogeneity.

Authors:  Robert B Jenkins; Margaret R Wrensch; Derek Johnson; Brooke L Fridley; Paul A Decker; Yuanyuan Xiao; Thomas M Kollmeyer; Amanda L Rynearson; Stephanie Fink; Terri Rice; Lucie S McCoy; Chandralekha Halder; Matthew L Kosel; Caterina Giannini; Tarik Tihan; Brian P O'Neill; Daniel H Lachance; Ping Yang; Joseph Wiemels; John K Wiencke
Journal:  Cancer Genet       Date:  2011-01

2.  Case Report: Heterozygous Germline Variant in EIF6 Additional to Biallelic SBDS Pathogenic Variants in a Patient With Ribosomopathy Shwachman-Diamond Syndrome.

Authors:  Ibrahim Taha; Selena Foroni; Roberto Valli; Annalisa Frattini; Pamela Roccia; Giovanni Porta; Marco Zecca; Elena Bergami; Marco Cipolli; Francesco Pasquali; Cesare Danesino; Claudia Scotti; Antonella Minelli
Journal:  Front Genet       Date:  2022-08-12       Impact factor: 4.772

3.  Evaluation of the association between the JAK2 46/1 haplotype and chronic myeloproliferative neoplasms in a Brazilian population.

Authors:  Sarah Pagliarini-e-Silva; Bruna Cunha Santos; Elizangela Mendes de Figueiredo Pereira; Mari Ellen Ferreira; Elaine Cristina Baraldi; Ana Maria Sell; Jeane Eliete Laguila Visentainer
Journal:  Clinics (Sao Paulo)       Date:  2013-01       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.